Trial Profile
A Phase I, Open-Label, Single Sequence, Crossover Study Evaluating the Safety and the Pharmacokinetics of Lopinavir/Ritonavir and Eltrombopag Given Alone and When Co-Administered in Healthy Adult Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Sep 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary) ; Lopinavir/ritonavir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 30 Aug 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 06 Feb 2009 New trial record